Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-16.50% $5.06
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 108.19 mill |
EPS: | -2.31 |
P/E: | -2.19 |
Earnings Date: | Mar 27, 2024 |
SharesOutstanding: | 21.38 mill |
Avg Daily Volume: | 1.089 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.19 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.37x |
Company: PE -2.19 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.391 (-92.27%) $-4.67 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 4.33 - 5.79 ( +/- 14.41%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-07 | Izumi Raquel E. | Buy | 123 750 | Stock Option (right to buy) |
2024-03-07 | Seelenberger Alexander A. | Buy | 93 750 | Stock Option (right to buy) |
2024-03-07 | Hamdy Ahmed Md | Buy | 146 746 | Stock Option (right to buy) |
2024-03-07 | Thomas Tom C | Buy | 93 750 | Stock Option (right to buy) |
2023-08-11 | Seelenberger Alexander A. | Buy | 10 500 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 97 transactions |
Buy: 7 261 732 | Sell: 1 766 942 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $5.06 (-16.50% ) |
Volume | 0.602 mill |
Avg. Vol. | 1.089 mill |
% of Avg. Vol | 55.27 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.